The trial was authorized by the US Food and Drug Administration (FDA) * Phase II of the clinical trials is expected to begin in June 2007
Beauline R. X., a drug development company, announced the start of clinical tests to determine the degree of binding of BL-1020 to dopamine receptors in the human brain, which is a measure of the drug's clinical effectiveness. The clinical tests will begin following the permit the company recently received from the American Food and Drug Administration (FDA), and will be conducted in Sweden. The results of the tests will provide additional data on the effectiveness and safety of BL-1020.
Bioline R.X. A Phase II clinical trial in patients for BL-1020 is expected to begin in late June, 2007, as planned, to determine the safety and tolerability of the drug. The test sites have already been selected in Romania and Israel, and a preliminary meeting of researchers is planned for mid-June.
"We attach importance to the results of the trials, and believe that they will provide us with very valuable information about the efficacy of BL-1020 and its mechanism of action," said Dr. Maurice Lester, CEO of Bioline Rx. "We believe that BL-1020 has great potential to be the next generation of antipsychotic drugs, effective drugs with minimal side effects that will allow for optimal treatment."
About BL-1020
BL-1020 is an antipsychotic drug taken by mouth to treat schizophrenia. According to tests conducted in models of schizophrenia in laboratory animals and in phase I of clinical tests in humans, it was found that the drug is effective in treating the symptoms of the disease and at the same time significantly reduces the degree of side effects compared to the drugs accepted for the treatment of this disease.
The rights for BL-1020 were purchased from the technology commercialization companies, Ramot Company of Tel Aviv University and the Research and Development Company of Bar Ilan University. The drug is the product of the invention of Professor Avraham Nodelman from the Department of Biochemistry at Bar Ilan University, and Dr. Ada Rafali, Professor Avraham Weizman and Dr. Irit Gil-Ed from the Sackler Faculty of Medicine at Tel Aviv University.
4 תגובות
My daughter suffers from schizophrenia, the variety of medications that exist still do not manage to balance her, is the medication being used 25/9/2009
Come on, father, why didn't you do the experiments on patients? What does Rami do all day? Why didn't he finish this drug? And you, from June 2007 are you sleeping or what?
post Scriptum. - Why did you publish the name of Dalia Ziskind (oops, sorry. The name escaped me).
Since June 2007, when you were supposed to conduct an experiment on patients, has the experiment been conducted? And what were the results? Thank you for your reply as soon as possible
Avi Bilovski I suffer from hypoxorphania, maybe the heat will help me